Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells

The combination of intravenous Proemend(®) containing fosaprepitant meglumine, a prodrug for fosaprepitant (FAP), and Tween 80 and chemotherapy with anthracyclines, such as epirubicin (EPI), can cause infusion-site adverse events in clinical practice. In immortalized human umbilical vein endothelial...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Miho, Oda, Keisuke, Ichinose, Takashi, Mizuguchi, Marie, Tominaga, Shoko, Omoda, Kei, Mori, Nobuhiro, Maeda, Yorinobu, Nishida, Toshihiro, Murakami, Teruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494625/
https://www.ncbi.nlm.nih.gov/pubmed/36238357
http://dx.doi.org/10.3892/ol.2022.13506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494625/
https://www.ncbi.nlm.nih.gov/pubmed/36238357
http://dx.doi.org/10.3892/ol.2022.13506

Ejemplares similares